CDK2 and cancer: Wee1 inhibitors have thus far been clinically limited in part due to toxicity (40), but ongoing trials are investigating PKMYT1 inhibition (such as RP-6306; ref. 44) and CDK2 inhibition (45) selectively in CCNE1-amplified cancers (46, 47).